Abstracts Archive - Page 2263 of 2605 - ACR Meeting Abstracts

Abstract Number: 2549 • 2013 ACR/ARHP Annual Meeting
Can Biomarkers Provide An Objective Standard Against Which To Assess Lupus Clinical Endpoint Measures?
Aikaterini Thanou¹, Melissa E. Munroe², Stan Kamp³, Joel M. Guthridge⁴, Judith A. James⁵ and Joan T. Merrill⁶, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Despite the heterogeneity of SLE, specific pathways of immune dysregulation characterize significant subsets of patients. We examined cytokines reflecting IL6-TH17 pathology in lupus as…
Abstract Number: 2550 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome
Esther Rodriguez-Almaraz¹, Elena Gonzalo-Gil², Ignacio Herráiz³, Paula I Gómez-Arriaga³, Paloma Vallejo³, Elena A López-Jiménez⁴, María Galindo Izquierdo¹ and Alberto Galindo Izquierdo³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Grupo de Investigación en Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Fetal Medicine Unit, Department of Obstetrics and Gynecology. Hospital Universitario 12 de Octubre., Madrid, Spain, ⁴Department of Biochemistry. Hospital Universitario 12 de Octubre., Madrid, Spain
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of preeclampsia (PE), which can be confused with lupus nephritis. Our objective was to…
Abstract Number: 2551 • 2013 ACR/ARHP Annual Meeting
Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
David A. Isenberg¹, David Wofsy², Yong Li³, Daiana Licu⁴, Stephen D. Wax⁵, Caroline Gordon⁶ and Claudia Pena Rossi⁴, ¹Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ²Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ³EMD Serono, Rockland, MA, ⁴Merck Serono S.A., Geneva, Switzerland, ⁵Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B cell stimulating factors BLyS and APRIL. We examined the pharmacodynamic (PD) effects of atacicept in patients…
Abstract Number: 2523 • 2013 ACR/ARHP Annual Meeting
Inflammatory Arthritis Activity During Pregnancy In Systemic Lupus Erythematosus
Sara K. Tedeschi, Bonnie L. Bermas and Karen H. Costenbader, Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While overall SLE disease and lupus nephritis activity during pregnancy have been studied, the activity of inflammatory arthritis during SLE pregnancy has not been…
Abstract Number: 2512 • 2013 ACR/ARHP Annual Meeting
Smoking Is Associated With More Severe Skin Disease In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Victoria P. Werth¹, Munther A. Khamashta², Gabor G. Illei³, Stephen Yoo³, Liangwei Wang⁴ and Warren Greth³, ¹Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁴Biostatistics, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: The influence of smoking on the severity of cutaneous manifestations in adults with moderate to severe SLE was assessed in an ongoing international, multi-center,…
Abstract Number: 2513 • 2013 ACR/ARHP Annual Meeting
Anti-Mullerian Hormone In Patients With Systemic Lupus Erythematosus
Chiara Tani¹, Sabrina Vagnani², Linda Carli³, Giovanni Gallo⁴, Maria Rita Sessa⁵, Chiara Baldini⁶, Alessandra Della Rossa⁷, Rosaria Talarico⁸, Francesca Strigini³, Marco Maccheroni⁵, Stefano Bombardieri³ and Marta Mosca³, ¹Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Departement of Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁵S. Chiara Hospital, Pisa, Italy, ⁶University of Pisa, Rheumatology Unit, Pisa, Italy, ⁷Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁸Rheumatology Unit, Pisa, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) frequently affects women in childbearing age; disease related factors and treatment can interfere with ovarian function. Anti-Mullerian-hormone (AMH) levels are…
Abstract Number: 2514 • 2013 ACR/ARHP Annual Meeting
The Brief Index of Lupus Damage, a Patient-Reported Measure of Lupus Damage, Is Sensitive to Change
Patricia P. Katz¹, Laura Trupin², Stephanie Rush³ and Jinoos Yazdany², ¹Medicine, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Extending lupus research outside of the clinical setting remains a challenge, in part due to the complexity of measuring disease damage. Previously, we…
Abstract Number: 2515 • 2013 ACR/ARHP Annual Meeting
Social Capital: A Novel Platform For Understanding Social Determinants Of Health In Systemic Lupus Erythematosus
Susan Kim¹, Carol Mancuso², Wei-Ti Huang³ and Doruk Erkan⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine, Hospital for Special Surgery, NY, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology Dept, Hospital for Special Surgery, New York, NY
Background/Purpose: Social capital is the degree of connectedness, and the extent and quality of social relations, networks, and interactions in a given population. The objective…
Abstract Number: 2516 • 2013 ACR/ARHP Annual Meeting
Plasma Microparticles Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Michelle Petri¹, Melissa Nastacio², Hong Fang¹, Thomas Kickler¹, Jayesh Jani¹ and Laurence S. Magder³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Thrombosis in SLE is highly associated with antiphospholipid antibodies, yet the majority of those with antiphospholipid antibodies never have a thrombotic event. Plasma microparticles…
Abstract Number: 2517 • 2013 ACR/ARHP Annual Meeting
The Interferon-Alpha Signature In Patients With Serologically Active Clinically Quiescent Systemic Lupus Erythematosus
Amanda J. Steiman¹, Murray B. Urowitz², Dominique Ibanez², Carolina Landolt-Marticorena³, Joan E. Wither⁴ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Interferon-α (IFN-α) plays a prominent pro-inflammatory role in SLE. Studies suggest clinical/serologic discordance may illuminate systemic lupus erythematosus (SLE) pathophysiology, as peripheral IFN-α production…
Abstract Number: 2518 • 2013 ACR/ARHP Annual Meeting
Only BAFF mRNA, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year
Eric Zollars¹, Hong Fang², Jadwiga Bienkowska³, Julie Czerkowicz⁴, Ann Ranger⁴, Norm Allaire⁵, Alice Thai⁴, Jeff Browning⁶, Laurence S. Magder⁷ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA, ⁶Boston University School of Medicine, Boston, MA, ⁷Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: B-cell–activating factor (BAFF; also known as B lymphocyte stimulator or BLyS) is a prominent factor in the selection and survival of B cells. BAFF…
Abstract Number: 2519 • 2013 ACR/ARHP Annual Meeting
A Systemic Lupus Erythematosus (SLE) Diagnostic Test Based On DNA Methylation Signatures From Peripheral Blood Mononuclear Cells
David W. Anderson¹, Robert Shoemaker², Kurt Krummel³, Zachary Hornby⁴ and Jonathan E. Lim¹, ¹Research and Development, IGNYTA, Inc., San Diego, CA, ²Bioinformatics, IGNYTA, Inc., San Diego, CA, ³Research and Development-Assay Development, IGNYTA, Inc., San Diego, CA, ⁴Business Development, IGNYTA, Inc., San Diego, CA
Background/Purpose: The heterogeneous nature of SLE and a lack of reliable biomarkers make SLE a challenge to classify in patients. A differential diagnosis of SLE…
Abstract Number: 2520 • 2013 ACR/ARHP Annual Meeting
A Freely Accessible Toolbox For Patient-Reported Outcomes: Development and Systematic Literature Review For Lupus Instruments
Isabel Castrejón¹, Loreto Carmona^2,3, Robin Christensen⁴, Till Uhlig⁵, Birgit Prodinger⁶, Francis Guillemin⁷, Marieke Scholte-Voshaar⁸ and Laure Gossec^9,10, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ³Institute for Musculoskeletal Health, Madrid, Spain, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶ICF Research Branch, Swiss Paraplegic Group, Nottwil, Switzerland, Notwill, Switzerland, ⁷CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁸EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ⁹Cochin University Hospital, Paris, France, ¹⁰Rheumatology, PitiéSalpêtrière Hospital, Pierre et Marie Curie University, Paris, France
Background/Purpose: Patient self-report has become prominent in the assessment of rheumatic and musculoskeletal diseases (RMD). In a workshop on priorities in PROs in 2009 it…
Abstract Number: 2521 • 2013 ACR/ARHP Annual Meeting
Correlation Of Anti Single and Double Stranded DNA Antibodies and Disease Activity In Systemic Lupus Erythematosus
Cecilia Catoggio, Cecilia Reimundes and Carlos Edgardo Perandones, Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina
Background/Purpose: Anti DNA antibodies are considered a hallmark of systemic lupus erythematosus (SLE). Anti double stranded DNA antibody (dsDNA) is part of the SLE classification…
Abstract Number: 2522 • 2013 ACR/ARHP Annual Meeting
Novel Autoantibody Against CAF-1 Is a Biomarker For CNS Manifestation in patients With SLE
Kentaro Doe¹, Kazuhisa Nozawa², Kaori Hiruma², Yusuke Yamada¹, Yuko Matsuki¹, Soichiro Nakano¹, Michihiro Ogasawara³ and Yoshinari Takasaki⁴, ¹Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of internal medicine and rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Proliferating cell nuclear antigen (PCNA) is known to be an autoantigen specifically recognized by antibodies in sera from patients with systemic lupus erythematosus (SLE). Although a prevalence of anti-PCNA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].